NaV1.5-CARED Research Program
A European research program
NaV1.5-CARED consortium proposes to capitalize on its largest worldwide cohort of patients with inherited cardiac electrical disorders to conduct genetics studies and uncover regulatory regions and proteins that modulate NaV1.5 expression and function.
Our goal is to develop and validate innovative therapies to restore the function of NaV1.5.
NaV1.5-CARED is coordinated by Julien Barc, Inserm researcher at l'institut du Thorax (Nantes, France),
specialized in genetics, epigenetics and molecular mechanisms
associated with inherited cardiac arrhythmia at risk of sudden cardiac death.
Consortium
NaV1.5-CARED brings together 8 different scientific entities, from 3 European countries.
A scientific advisor board and an Ethics advisor have been invited to join our consortium to bring their expertise on scientific and ethical issues.
Funding
NaV1.5-CARED has been selected in the 2022 EIC Pathfinder Challenge "Cardiogenomics" programme that provides funding for projects in any field of science or technology, based on high-risk/high-gain science-towards-technology breakthrough interdisciplinary research.
This year, the European jury has evaluated 436 proposals from 29 countries, based on scientific quality and innovative criteria, but also depending on their medical and socio-economical benefits.
44 projects, including NaV1.5-CARED, have been funded.
NaV1.5-CARED has 5 years and an endowment of 4 546 204€ to identify variants associated with ventricular arrhythmia and conduction defects, generate PRS relevant to stratify the risk of arrhythmia and degree of conduction defect, and identify new therapeutic that will be evaluated in dedicated and high-throughput human cardiomyocytes derived induced pluripotent cell models.
Work Packages
NaV1.5-CARED Work Packages
The project consists of four scientific work packages:
WP1: Standardization and exploitation of the largest worldwide patient databases presenting inherited electrical cardiac diseases at risk of sudden cardiac death
WP2: Identification of new actionable genetic variants associated with cardiac electrical defects and risk of sudden cardiac death and clinical application
WP3: Identification of potential therapeutic targets among the diseases-associated non-coding regulatory regions and NaV1.5 modulating protein partners and development of a proof of concept for first class therapies
WP4: Translational development of new gene therapeutic interventions to restore cardiac sodium channel function